دورية أكاديمية
Seroprevalence of antibodies against SARS-CoV-2 in the school community in Campo Grande, state of Mato Grosso do Sul, Brazil, October 2021-November 2022.
| العنوان: | Seroprevalence of antibodies against SARS-CoV-2 in the school community in Campo Grande, state of Mato Grosso do Sul, Brazil, October 2021-November 2022. |
|---|---|
| المؤلفون: | Stutz C; Fiocruz Ceará, Fundação Oswaldo Cruz (Fiocruz), Eusébio, Ceará, Brazil.; Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Ciências Farmacêuticas, Alimentos e Nutrição (FACFAN), Fundação Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil., Alcantara DMC; Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz (Fiocruz), Campo Grande, Mato Grosso do Sul, Brazil., Dos Santos CM; Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz (Fiocruz), Campo Grande, Mato Grosso do Sul, Brazil., Torres JM; Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz (Fiocruz), Campo Grande, Mato Grosso do Sul, Brazil., Rodrigues R; Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz (Fiocruz), Campo Grande, Mato Grosso do Sul, Brazil., Marcon GEB; Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz (Fiocruz), Campo Grande, Mato Grosso do Sul, Brazil., Ferreira EC; Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz (Fiocruz), Campo Grande, Mato Grosso do Sul, Brazil.; Programa de Pós-graduação em Doenças Infecciosas e Parasitárias, Faculdade de Medicina (FAMED), Fundação Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil., Sarti ECFB; Instituto Integrado de Saúde (INISA), Fundação Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil., de Oliveira TF; Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz (Fiocruz), Campo Grande, Mato Grosso do Sul, Brazil., Mendes FML; Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz (Fiocruz), Campo Grande, Mato Grosso do Sul, Brazil., Lemos EF; Universidade Estadual de Mato Grosso do Sul (UEMS), Campo Grande, Mato Grosso do Sul, Brazil., Demarchi LHF; Laboratório Central de Saúde Pública do Estado de Mato Grosso do Sul (LACEN-MS), Campo Grande, Mato Grosso do Sul, Brazil., Lichs GGC; Laboratório Central de Saúde Pública do Estado de Mato Grosso do Sul (LACEN-MS), Campo Grande, Mato Grosso do Sul, Brazil., Zardin MCSU; Laboratório Central de Saúde Pública do Estado de Mato Grosso do Sul (LACEN-MS), Campo Grande, Mato Grosso do Sul, Brazil., Gonçalves CCM; Programa de Pós-graduação em Doenças Infecciosas e Parasitárias, Faculdade de Medicina (FAMED), Fundação Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil.; Secretaria de Estado de Saúde de Mato Grosso do Sul, Secretaria Adjunta de Estado, Campo Grande, Mato Grosso do Sul, Brazil., Guilhermino JF; Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz (Fiocruz), Campo Grande, Mato Grosso do Sul, Brazil., Perdomo RT; Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Ciências Farmacêuticas, Alimentos e Nutrição (FACFAN), Fundação Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil.; Laboratório de Biologia Molecular e Cultura Celular da Faculdade de Ciências Farmacêuticas, Alimentos e Nutrição (FACFAN), Fundação Universidade Federal de Mato Grosso do Sul (UFMS), Campo Grande, Mato Grosso do Sul, Brazil., Fernandez ZDC; Fiocruz Mato Grosso do Sul, Fundação Oswaldo Cruz (Fiocruz), Campo Grande, Mato Grosso do Sul, Brazil. |
| المصدر: | Frontiers in immunology [Front Immunol] 2024 Mar 26; Vol. 15, pp. 1354786. Date of Electronic Publication: 2024 Mar 26 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | SARS-CoV-2* , COVID-19*/epidemiology, Adolescent ; Adult ; Child ; Humans ; Female ; Brazil/epidemiology ; Bayes Theorem ; Seroepidemiologic Studies ; Antibodies, Viral ; Immunoglobulin G ; Immunoglobulin M |
| مستخلص: | Introduction: With the reopening of schools during the coronavirus disease 2019 (COVID-19) pandemic, it was imperative to understand the role of students and education professionals in the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this paper, we determined the seroprevalence of the SARS-CoV-2 anti-nucleocapsid antibodies in the school community in Campo Grande, the capital and most populous city of the state of Mato Grosso do Sul (Brazil) and evaluated its association with sex, school level, and school type. Materials and Methods: The survey was carried out in 20 public and private schools in the urban region of Campo Grande using the TR DPP ® COVID-19 immunoglobulin M/immunoglobulin G (IgM/IgG) kit from the Immunobiological Technology Institute (Bio-Manguinhos, Rio de Janeiro, Brazil). Testing was carried out in three periods: from October to December 2021; from March to July 2022; and from August to November 2022. The participants were students aged 6-17 years enrolled in primary or secondary schools and professionals of different ages and roles. Results: During the first testing period, 162 participants were seropositive for the IgM and/or IgG anti-nucleocapsid SARS-CoV-2 antibodies, with an estimated seroprevalence of 19.6% using Bayesian multilevel regression. In the second period, 251 participants were seropositive (estimated seroprevalence, 34.6%), while in the third period, 393 participants were seroconverted (estimated seroprevalence, 56.7%). In 2022, there was an increase in the seroconversion rate compared to that in 2021. The most frequently described acute manifestations in the three periods were fever, headache, sore throat, and runny nose. In terms of the demographic profile, there was no predominance of seropositivity between the sexes, although women represented approximately 70% of the study population. There were also no differences between students and school staff. Discussion: The results made it possible to evaluate the extent of SARS-CoV-2 transmission in the school community through immunity developed against the virus, in addition to providing information about COVID-19 symptoms in children, adolescents, and adults. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Stutz, Alcantara, Santos, Torres, Rodrigues, Marcon, Ferreira, Sarti, Oliveira, Mendes, Lemos, Demarchi, Lichs, Zardin, Gonçalves, Guilhermino, Perdomo and Fernandez.) |
| References: | Epidemiol Infect. 2022 Oct 19;150:e177. (PMID: 36345855) Front Public Health. 2022 Feb 22;10:837513. (PMID: 35296050) Clin Infect Dis. 2021 Jul 15;73(2):e458-e465. (PMID: 32649743) N Engl J Med. 2022 Apr 21;386(16):1532-1546. (PMID: 35249272) J Med Virol. 2021 Feb;93(2):1057-1069. (PMID: 32761898) Pediatr Infect Dis J. 2023 Mar 1;42(3):218-225. (PMID: 36730085) Front Med (Lausanne). 2022 May 20;9:849217. (PMID: 35669924) JAMA Pediatr. 2021 Jun 1;175(6):586-593. (PMID: 33480966) J Biomed Inform. 2009 Apr;42(2):377-81. (PMID: 18929686) Rev Saude Publica. 2023 Apr 14;57:6. (PMID: 37075390) ACS Sens. 2021 Mar 26;6(3):593-612. (PMID: 33544999) N Engl J Med. 2022 May 19;386(20):1899-1909. (PMID: 35353976) Lancet Child Adolesc Health. 2020 May;4(5):397-404. (PMID: 32272089) JAMA. 2020 Jun 16;323(23):2427-2429. (PMID: 32432657) Open Forum Infect Dis. 2022 Sep 07;9(9):ofac459. (PMID: 36193228) Int J Infect Dis. 2023 Apr;129:1-9. (PMID: 36724865) Science. 2020 Oct 16;370(6514):286-288. (PMID: 32958582) Lancet Public Health. 2020 May;5(5):e279-e288. (PMID: 32311320) Int J Infect Dis. 2021 Jul;108:20-26. (PMID: 33945867) PLoS Med. 2021 Sep 28;18(9):e1003777. (PMID: 34582457) Science. 2021 Jan 1;371(6524):79-82. (PMID: 33177105) BMJ. 2021 Mar 17;372:n616. (PMID: 33731327) Trop Med Health. 2020 Nov 23;48(1):91. (PMID: 33292755) Pediatr Res. 2023 Aug;94(2):434-442. (PMID: 36879079) Am J Epidemiol. 2016 Nov 1;184(9):644-651. (PMID: 27744384) Lancet Child Adolesc Health. 2020 Nov;4(11):807-816. (PMID: 32758454) Clin Infect Dis. 2021 May 4;72(9):1493-1496. (PMID: 32584967) Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8012-8018. (PMID: 34982465) PLoS Med. 2022 Dec 20;19(12):e1003913. (PMID: 36538517) JAMA. 2021 Oct 12;326(14):1436-1438. (PMID: 34473191) Lancet Reg Health Eur. 2021 Jun;5:100092. (PMID: 34104904) Science. 2021 Feb 5;371(6529):. (PMID: 33408181) Ann Intern Med. 2022 Sep;175(9):1258-1265. (PMID: 35785530) BMC Med Res Methodol. 2022 Jul 30;22(1):209. (PMID: 35907796) Nat Med. 2021 Jul;27(7):1230-1238. (PMID: 34035535) Microb Biotechnol. 2022 Apr;15(4):1035-1049. (PMID: 35182108) Int J Infect Dis. 2020 Apr;93:339-344. (PMID: 32198088) J Biomed Inform. 2019 Jul;95:103208. (PMID: 31078660) Nat Immunol. 2022 Feb;23(2):177-185. (PMID: 35105983) Microbiol Spectr. 2022 Oct 26;10(5):e0264121. (PMID: 36000897) Nat Med. 2020 Aug;26(8):1205-1211. (PMID: 32546824) Clin Microbiol Infect. 2021 Mar;27(3):331-340. (PMID: 33228974) PLoS One. 2022 Feb 16;17(2):e0263741. (PMID: 35171936) Lancet Glob Health. 2020 Nov;8(11):e1390-e1398. (PMID: 32979314) N Engl J Med. 2022 Jan 13;386(2):116-127. (PMID: 34942067) Clin Infect Dis. 2022 Oct 3;75(Suppl 2):S303-S307. (PMID: 35684958) |
| فهرسة مساهمة: | Keywords: COVID-19; adolescents; antibodies; children; educational institutions; serological survey |
| المشرفين على المادة: | 0 (Antibodies, Viral) 0 (Immunoglobulin G) 0 (Immunoglobulin M) |
| تواريخ الأحداث: | Date Created: 20240410 Date Completed: 20240411 Latest Revision: 20240412 |
| رمز التحديث: | 20240412 |
| مُعرف محوري في PubMed: | PMC11002276 |
| DOI: | 10.3389/fimmu.2024.1354786 |
| PMID: | 38596680 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2024.1354786 |